Drugs / Thrombate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05794165 | Sep 2023 → Nov 2026 expected | thrombotic disease, venous thromboembolism | Bryan Cotton | Enrolling by invitation | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-18 | Grifols Therapeutics LLC | Grifols receives expanded indication for THROMBATE III® (antithrombin III [human]) label in U.S., strengthening treatment options for pediatric patients grifols.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thrombate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05794165 ↗ |
| Route | Intravenous | “Bolus intravenous infusion of Thrombate” NCT05794165 ↗ |